Coxibs and cardiovascular side-effects: from light to shadow

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Gastroenterology

Background:

• Cyclooxygenase-2 (COX-2) selective inhibitors (coxibs) were developed to reduce gastrointestinal side effects associated with non-selective NSAIDs.
• Concerns regarding cardiovascular safety emerged with the withdrawal of rofecoxib due to increased cardiovascular events.
• This prompted re-evaluation of the safety profile of all selective COX-2 inhibitors.

Purpose of the Study:

• To compare marketed coxibs based on their clinical, pharmacological, and chemical properties.
• To investigate the potential mechanisms behind the cardiovascular effects of selective COX-2 inhibitors.
• To provide insights into the cardiovascular risks associated with this class of drugs.

Main Methods:

• Review of clinical data for marketed coxibs.
• Analysis of pharmacological properties of selective COX-2 inhibitors.
• Comparison of chemical structures and properties of various coxibs.

Main Results:

• Rofecoxib withdrawal highlighted significant cardiovascular risks.
• Evidence suggests potential cardiovascular risks may extend to other coxibs, including celecoxib.
• Cardiovascular toxicity might be a class effect or specific to individual coxib properties.

Conclusions:

• The cardiovascular safety of selective COX-2 inhibitors requires careful consideration.
• Further research is needed to elucidate the precise mechanisms of coxib-induced cardiovascular events.
• Understanding the distinct properties of each coxib is crucial for assessing patient risk.